Table 3 Drug-Related Adverse Events Occurring in ≥ 15% of Patients Who Received Vorinostat Monotherapy in the Vorinostat Clinical Trial Program (Data Cut-Off April 2008)
Adverse Event | No. (%) of Patients (N= 341) | |
|---|---|---|
| Â | All Grades | Grade 3 or 4 |
Fatigue | 211 (61.9) | 41 (12.0) |
Nausea | 190 (55.7) | 14 (4.1) |
Diarrhea | 168 (49.3) | 14 (4.1) |
Anorexia | 164 (48.1) | 17 (5.0) |
Vomiting | 112 (32.8) | 5 (1.5) |
Blood creatinine increased | 88 (25.8) | 2 (0.6) |
Weight decreased | 86 (25.2) | 4 (1.2) |
Hyperglycemia | 79 (23.2) | 10 (2.9) |
Thrombocytopenia | 71 (20.8) | 36 (10.6) |
Platelet count decreased | 65 (19.1) | 18 (5.3) |
Hemoglobin decreased | 60 (17.6) | 10 (2.9) |
Constipation | 60 (17.6) | 3 (0.9) |
Dysgeusia | 59 (17.3) | 0 (0.0) |